Group 1 - The core viewpoint of the news highlights the recent research conducted by the well-known private equity firm, Julong Investment, on a listed company, Baolait. The research indicates a mixed performance in terms of revenue and profit for Baolait in the first quarter of 2025 [1] - Baolait achieved operating revenue of 247,732,813.14 yuan, representing a year-on-year decrease of 7.17%, while net profit saw a significant year-on-year increase of 298.35% [1] - The company benefits from new policies that promote equipment upgrades, particularly in mid-to-high-end monitoring devices and blood dialysis equipment. The annual compound growth rate for dialysis patients is 12%, indicating a market opportunity for domestic alternatives [1] Group 2 - Baolait has expanded its blood dialysis products into overseas markets, although the overall scale remains relatively small. The production capacity for dialysis devices is distributed across Suzhou and Zhuhai, with dialysis powder and liquid products covering multiple regions nationwide [1] - The company has launched its self-developed PD600 peritoneal dialysis device, along with supporting tubing and information systems. Traditional peritoneal dialysis requires manual operation, while automated peritoneal dialysis can be performed at home during the night [1] - Baolait is advancing the research and development of intelligent medical devices, including the independent development of CRRT machines [1]

广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20250701 | |  特定对象调研分析师会议 | | | --- | --- | --- | | 投资者关系活 | 媒体采访业绩说明会 | | | 动类别 | 新闻发布会路演活动 | | | |  现场参观 | | | | 其他 | | | 时间 | 2025 年 月 8 日 | 7 | | 地点 | 宝莱特公司会议室 | | | 参与单位名称 | 新财富杂志社邱海波 | | | | 杨杰 聚隆投资 | | | | 国海证券 谢豪辉 | | | | 第一传媒（横琴）黄春森 | | | | Alveria Capital Brockwell Sim | | | | 广东锋华建设有限公司糜琼 | | | | 广东雄起文化有限公司杨毅 | | | 上市公司接待 | 董事会秘书兼副总裁 杨永兴 | | | 人员姓名 | 营销系统总经理兼肾病医疗销售总监 燕兆 | | | | 品牌中心主管 庄依晨 | | | | 证券事务代表 李韵妮 | | | | 证券事务专员 钟欣昊 | | | 投资者关系活 | 公司介绍环节： | | | 动主要内容 ...

Core Insights - The company reported a revenue of 36.726 billion yuan in 2024, reflecting a growth of 5.14%, with a net profit attributable to shareholders of 11.668 billion yuan, up by 0.74% [1] - In Q4 2024, the company experienced a revenue decline of 5.08% to 7.241 billion yuan, while net profit surged by 40.99% to 1.031 billion yuan [1] - The first quarter of 2025 saw a revenue drop of 12.12% to 8.237 billion yuan, with net profit decreasing by 16.81% to 2.629 billion yuan [1] Financial Performance - The overall gross margin for 2024 was 63.14%, a decrease of 1.08%, primarily due to changes in business structure and product pricing adjustments [2] - The company’s operating cash flow for 2024 was 12.432 billion yuan, an increase of 12.38% [1] - The gross margin for Q1 2025 improved by 6.57 percentage points to 62.53%, indicating that short-term adjustments may have been largely absorbed [2] Business Segments - The Life Information and Support segment generated 13.557 billion yuan in 2024, a decline of 11.11%, but the minimally invasive surgery business grew by over 30% [3] - The In Vitro Diagnostics segment achieved a revenue of 13.765 billion yuan, up by 10.82%, despite domestic challenges due to policy changes [3] - The Medical Imaging segment reported a revenue of 7.498 billion yuan, reflecting a growth of 6.60%, with high-end ultrasound models contributing significantly [3] International Expansion - The company’s international business grew by 21.28% in 2024, accounting for approximately 45% of total revenue, driven by high-end customer acquisition and local platform development [2] - The In Vitro Diagnostics international business saw over 30% growth, with local production projects initiated in 13 countries [3] Research and Development - The company maintained high R&D investment levels, with 4.008 billion yuan in 2024, representing 10.91% of revenue [4] - As of March 31, 2025, the company had applied for approximately 12,000 patents, with 5,973 patents granted [4] Shareholder Returns - The company distributed a total cash dividend of 7.602 billion yuan in 2024, with a cash dividend ratio of 65.15% [4] - A mid-term profit distribution plan for 2025 proposes a cash dividend of 1.710 billion yuan, reflecting strong profitability and commitment to shareholder returns [4]

长江商报记者发现，2020年至2023年，Ever Union已经完成了三轮减持，累计套现约50.55亿元。 公司称，减持是因股东自身资金需求。Ever Union已经套现超过50亿元，还缺钱吗？ 长江商报消息 ●长江商报记者 沈右荣实习生 赖海军 国内医疗器械巨头迈瑞医疗（300760.SZ）的股东又计划减持。 6月29日晚间，迈瑞医疗披露，公司特定股东Ever Union（H.K.）Limited（以下简称"Ever Union"）计划 在未来三个月内减持所持公司不超过500万股股份，即不超过公司总股本的0.41%。 迈瑞医疗是依靠并购等途径成长起来的医疗器械巨头，2024年，公司出资66.52亿元完成了惠泰医疗控 制权收购。 历经多年快速增长后，2024年，迈瑞医疗的业绩增速大幅放缓，今年一季度，公司营业收入、归母净利 润双降。 二级市场上，近年来，迈瑞医疗的股价震荡下行。7月1日，其收盘价226.50元/股，较2021年7月1日高 点跌超50%，股价跌回至2020年4月初的水平。 股东拟再减持套现11亿 迈瑞医疗的特定股东计划再次减持。 根据最新公告，迈瑞医疗收到了特定股东Ever Union减持计划 ...

Core Viewpoint - Mindray Medical aims to become one of the top ten or even top five medical device companies globally, leveraging its strong competitive position in the Chinese market, particularly in the monitoring equipment sector [4]. Group 1: Investor Relations Activities - Mindray Medical conducted a series of investor relations activities from May 19 to June 27, 2025, attracting 382 institutions and 713 investors [3]. Group 2: Competitive Advantages - The company's success is attributed to its meticulous attention to detail and solid execution across R&D, management, and sales, alongside a strong focus on employee training and welfare [5]. Group 3: Addressing Performance Challenges - Mindray identified reasons for slowing growth, including post-pandemic demand decline and trade friction, and is focusing on high-end market needs and overseas expansion to regain rapid growth [6]. Group 4: Domestic Policy Adaptation - The company views centralized procurement policies as a necessary step towards market maturity in China, which ultimately presents opportunities for leading domestic firms [7]. Group 5: International Strategy - Mindray aims for international revenue to account for 70% of its total, with over 60 overseas subsidiaries and a focus on local production and compliance with international regulations [8]. Group 6: Business Transformation - The company is preparing for a transformation in its business model by acquiring Huatai to enhance its core technology and expand into high-value consumables [9]. Group 7: Product Development and Market Position - Mindray is narrowing the gap with Roche in the chemiluminescence sector through strategic acquisitions and local production, with confidence in competing with imported brands [10]. Group 8: Data Integration and Device Advantage - The "Ruizhi Lian" data platform integrates with most mainstream devices, providing comprehensive and accurate patient data, which is a significant competitive edge [12]. Group 9: R&D Resource Allocation - The company balances R&D resources to support both core and emerging businesses, ensuring stability in main operations while fostering new growth areas [13]. Group 10: Personalized Product Development - Mindray conducts market research in target countries during product development, ensuring that products meet local clinical needs before full market launch [14]. Group 11: IVD Product Line Improvements - Mindray's MT8000 product line addresses inefficiencies found in imported brands, with ongoing efforts to enhance functionality and adapt to European market needs [15]. Group 12: MPI System Adaptation - The company is refining its MPI system to better suit the needs of its IT and consumable businesses, ensuring rapid iteration and effective project execution [16]. Group 13: Growth Challenges and Strategies - Mindray recognizes its limitations in marketing and local delivery for high-value consumables and is considering both internal development and acquisitions to address these gaps [18]. Group 14: "Sanrui" Ecosystem Strategy - The "Sanrui" ecosystem model is designed to integrate clinical data and enhance automation and intelligence in medical devices, with plans for local deployment and information security [19]. Group 15: Innovation in Product Development - Mindray emphasizes technical innovation, focusing on user needs and product performance, as demonstrated by the successful launch of its ultrasound knife [20]. Group 16: Company Overview - Founded in 1991, Mindray Medical is China's largest medical device manufacturer, with a global presence and a strong R&D team [21]. Group 17: Financial Performance - In 2024, Mindray reported a revenue of 36.73 billion, a 5.1% increase year-on-year, with a net profit of 11.67 billion, reflecting a 0.7% growth [22].

Core Viewpoint - The company is expected to see a turning point in the second half of the year driven by innovation, mergers and acquisitions, and international expansion, with a stable growth rate of around 20% in recent years and high profitability levels [1] Group 1: Financial Performance - The company's revenue and net profit attributable to shareholders are projected to grow at a CAGR of 16.7% and 23.98% respectively from 2014 to 2024 [1] - The anticipated decline in growth rate for 2024 is primarily due to tight local government finances and delays in regular bidding processes [1] - The company is expected to achieve a sequential performance increase in the second half of the year, supported by the rapid growth of medical special bonds and improvements in bidding data [1] Group 2: Business Expansion and Market Presence - By the end of 2024, the company will have covered nearly 110,000 medical institutions in China and over 190 countries and regions globally [2] - The life information and support segment, including products like monitors and anesthesia machines, remains the market leader domestically and ranks among the top three globally, with international business expected to achieve double-digit growth in 2024 [2] - The IVD segment has seen significant growth in international business, with over 30% year-on-year growth driven by deep integration and localization strategies [2] Group 3: Strategic Initiatives - The company is accelerating its AI business layout, integrating and innovating existing products, and developing the "Sanrui" digital solution to enhance product volume and penetrate high-end domestic and international markets [1][3] - The company has established 63 overseas subsidiaries and continues to pursue domestic and international acquisitions to enrich its product matrix and enhance global channel layout [3] - The company is focusing on high-end product upgrades and breakthroughs in high-end customer acquisition, with overseas market share currently at only 3% [3] Group 4: Profit Forecast - The company is projected to achieve revenues of 400.25 billion, 450.05 billion, and 512.66 billion yuan in 2025, 2026, and 2027 respectively, with year-on-year growth rates of 8.98%, 12.44%, and 13.91% [4] - The net profit attributable to shareholders is expected to reach 125.92 billion, 143.72 billion, and 165.40 billion yuan for the same years, with growth rates of 7.91%, 14.13%, and 15.09% respectively [4]

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 国家倡导的创新，旨在推动各行业掌握核心技术，为国家发展贡献力量。 迈瑞将继续秉持这一理念，努力提升自身实力，为国家的医疗事业和科技进 步做出更大贡献，同时争取早日实现医疗器械全球排名前十的市场地位。 问：公司究竟有什么独特的"绝招"和卓越的经营能力，能够在激烈的市 场竞争中取得出色的成绩，并保持这种差异化优势？这种优势是否能够长期 维持？ 证券代码：300760 证券简称：迈瑞医疗 编号：2025-004 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 | | □分析师会议 特定对象调研 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 路演活动 | | 活动类别 | 现场参观 | | | 投资者开放日、券商策略会等 其他 | | 参与单位名 382 称及人员姓 | 家机构 名参与人员，详见附件清单。 713 | | 名 | | | 2025 时间 | 年 月 日、5 月 日、6 月 日、6 月 日、6 月 5 19-23 26-30 3-5 12-13 18-20 | | 日、6 | ...

宝莱特：正在紧密进行CRRT机型的自主研发 智通财经6月19日电，宝莱特(300246.SZ)在机构调研中表示，在肾病医疗板块，公司将持续研发血液透 析差异化耗材，积极探索腹膜透析、CRRT等更多肾科医疗相关领域产品技术，推进G系列高端监护 仪、AED、除颤监护仪等有源产品研发进度，力争尽早取证上市。同时公司正在紧密进行CRRT机型的 自主研发，该新产品将会与生命信息支持整体解决方案相结合并成为创新成果一并推出。 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20250602 | |  特定对象调研分析师会议 | | --- | --- | | 投资者关系活 | 媒体采访业绩说明会 | | 动类别 | 新闻发布会路演活动 | | |  现场参观 | | | 其他 | | 时间 | 2025 年 6 月 17 日 | | 地点 | 宝莱特公司会议室 | | 参与单位名称 | 善思投资：詹世乾 | | | 世纪财通投资：何工 | | | 钟朝 钟亮 魏军 | | 上市公司接待 | 董事会秘书兼副总裁 杨永兴 | | 人员姓名 | 证券事务代表 李韵妮 | | | 证券事务专员 钟欣昊 | | | 公司介绍环节： | | | 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 | | | 售。公司作为中国最早一批研发制造医疗监护仪的民族企业，是国家发改 | | 投资者关系活 | 委授予的"国家多参数监护仪产业化基地"、工业和信息化部认定的"第八 | | 动主要内容介 | 批国家级制造业单项冠军企业"，目前公司的监护设备已覆盖数千家医疗 | ...

中国质量新闻网讯（许创业）近日，国家知识产权局发布了第二十五届中国专利奖授奖决定，来自深圳 坪山的比亚迪股份有限公司、深圳市联赢激光股份有限公司、富满微电子集团股份有限公司、深圳新宙 邦科技股份有限公司、深圳邦健生物医疗设备股份有限公司、深圳市曼恩斯特科技股份有限公司等分别 荣获不同奖项。其中在新能源汽车产业领域厚积薄发的比亚迪，本次在专利和外观设计上均荣获一项金 奖。 近年来，坪山企业展现出强大的创新能力和知识产权管理能力。以比亚迪为代表的头部企业，在高价值 专利创造上保持了强大的实力和技术创新优势；辖区生物医药、新能源、智能制造等战略新兴产业呈现 蓬勃发展的良好势头，推动辖区创新主体在技术创新领域结果。 坪山区通过深入实施创新驱动发展和知识产权强区战略，全面推进知识产权高质量创造、高效益运用、 高标准保护、高品质服务。PCT国际专利申请量持续增长，高校和科研机构专利转化有新突破，知识产 权服务业规上企业营收增速全市居前，深圳市市场监督管理局坪山监管局查处重大侵权盗版案件获国家 版权局奖励。 2024年，坪山区专利授权总量超1.1万件，其中发明专利授权量占比超1/4；有效发明专利同比增长 24.03%，有效 ...